Viking has long been viewed as a takeover target, given the positive data from early VK2735 trials. The company’s most recent ...

Viking (VKTX) is in the midst of a phase 2a dosing trial of its oral obesity drug VK2735, with a data readout expected in the second half of the year. The company is expected to launch a phase 3 trial ...

The findings were published online in the CHEST Journal on December 30, 2024.

Scilex (SCLX) announced that it has entered into an amendment to its existing license agreement with Romeg Therapeutics, entered into in June ...

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...

E3 LITHIUM LTD. (TSXV: ETL) (FSE: OW3) (OTCQX: EEMMF), "E3 Lithium" or the "Company," a leader in Canadian lithium, is proud ...

Risk for pancreatitis was not elevated among users of tirzepatide relative to placebo, despite the presence of elevated pancreatic enzymes.

Anavex's financial health is stable with cash runway into 2028, but rising expenses are expected. Click here to find out why ...

Explore our new AAV Titer ELISA and AAV Antibody Assay Kits, designed for exceptional specificity, sensitivity, and accuracy ...

A recent study published in the Harm Reduction Journal documents the arrival of xylazine to the San Diego-Tijuana border ...

NDAQ:RAPP) Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders ...

The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over competitors’ more frequent regimens.